Chesapeake Capital Corp IL Purchases New Shares in COMPASS Pathways plc (NASDAQ:CMPS)

Chesapeake Capital Corp IL purchased a new position in COMPASS Pathways plc (NASDAQ:CMPS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 22,752 shares of the company’s stock, valued at approximately $189,000.

Other large investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its position in shares of COMPASS Pathways by 7.6% in the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock valued at $22,915,000 after acquiring an additional 186,040 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth $4,812,000. Quest Partners LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter worth $33,000. Jump Financial LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $371,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of COMPASS Pathways by 4.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 110,939 shares of the company’s stock worth $971,000 after buying an additional 4,981 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on CMPS. Morgan Stanley assumed coverage on shares of COMPASS Pathways in a research note on Monday, April 1st. They set an “overweight” rating and a $30.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, June 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Monday, May 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways currently has an average rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Price Performance

NASDAQ:CMPS traded up $0.03 on Friday, hitting $7.30. The stock had a trading volume of 169,923 shares, compared to its average volume of 331,124. The company has a fifty day moving average price of $6.98 and a two-hundred day moving average price of $8.70. COMPASS Pathways plc has a 1-year low of $5.01 and a 1-year high of $12.75. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.03). As a group, equities research analysts predict that COMPASS Pathways plc will post -2.24 earnings per share for the current year.

Insider Activity

In related news, major shareholder George Jay Goldsmith sold 9,621 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $8.29, for a total value of $79,758.09. Following the sale, the insider now directly owns 3,966,052 shares in the company, valued at approximately $32,878,571.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.25% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.